193 related articles for article (PubMed ID: 36059554)
1. Heterologous immunization with adenovirus vectored and inactivated vaccines effectively protects against SARS-CoV-2 variants in mice and macaques.
He Q; Mao Q; Zhang J; Gao F; Bai Y; Cui B; Liu J; An C; Wang Q; Yan X; Yang J; Song L; Song Z; Liu D; Yuan Y; Sun J; Zhao J; Bian L; Wu X; Huang W; Li C; Wang J; Liang Z; Xu M
Front Immunol; 2022; 13():949248. PubMed ID: 36059554
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity of an adenovirus-vectored bivalent vaccine against wild type SARS-CoV-2 and Omicron variants in a murine model.
Ji Y; Sui X; Miao W; Wang C; Wang Q; Duan Z; Wei B; Wu D; Wei M; Shao J; Zheng X; Zhu T
Vaccine; 2024 Feb; 42(6):1292-1299. PubMed ID: 38296705
[TBL] [Abstract][Full Text] [Related]
3. Preclinical evaluation of safety and immunogenicity of a primary series intranasal COVID-19 vaccine candidate (BBV154) and humoral immunogenicity evaluation of a heterologous prime-boost strategy with COVAXIN (BBV152).
Sunagar R; Prasad SD; Ella R; Vadrevu KM
Front Immunol; 2022; 13():1063679. PubMed ID: 36569867
[TBL] [Abstract][Full Text] [Related]
4. Neutralizing antibody levels associated with injectable and aerosolized Ad5-nCoV boosters and BA.2 infection.
Wang F; Huang B; Deng Y; Zhang S; Liu X; Wang L; Liu Q; Zhao L; Tang L; Wang W; Wang X; Ye F; Hu W; Yang H; Wang S; Ren J; Liu X; Wang C; Guan X; Wang R; Zheng Y; Zhang X; Zheng H; Wu D; An Z; Xu W; Rodewald LE; Gao GF; Yin Z; Tan W
BMC Med; 2023 Jul; 21(1):233. PubMed ID: 37400857
[TBL] [Abstract][Full Text] [Related]
5. Heterologous saRNA Prime, DNA Dual-Antigen Boost SARS-CoV-2 Vaccination Elicits Robust Cellular Immunogenicity and Cross-Variant Neutralizing Antibodies.
Rice A; Verma M; Voigt E; Battisti P; Beaver S; Reed S; Dinkins K; Mody S; Zakin L; Tanaka S; Morimoto B; Olson CA; Gabitzsch E; Safrit JT; Spilman P; Casper C; Soon-Shiong P
Front Immunol; 2022; 13():910136. PubMed ID: 35911728
[TBL] [Abstract][Full Text] [Related]
6. Boosting with heterologous vaccines effectively improves protective immune responses of the inactivated SARS-CoV-2 vaccine.
Zhang J; He Q; An C; Mao Q; Gao F; Bian L; Wu X; Wang Q; Liu P; Song L; Huo Y; Liu S; Yan X; Yang J; Cui B; Li C; Wang J; Liang Z; Xu M
Emerg Microbes Infect; 2021 Dec; 10(1):1598-1608. PubMed ID: 34278956
[TBL] [Abstract][Full Text] [Related]
7. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
Costa Clemens SA; Weckx L; Clemens R; Almeida Mendes AV; Ramos Souza A; Silveira MBV; da Guarda SNF; de Nobrega MM; de Moraes Pinto MI; Gonzalez IGS; Salvador N; Franco MM; de Avila Mendonça RN; Queiroz Oliveira IS; de Freitas Souza BS; Fraga M; Aley P; Bibi S; Cantrell L; Dejnirattisai W; Liu X; Mongkolsapaya J; Supasa P; Screaton GR; Lambe T; Voysey M; Pollard AJ;
Lancet; 2022 Feb; 399(10324):521-529. PubMed ID: 35074136
[TBL] [Abstract][Full Text] [Related]
8. Sequential heterologous immunization with COVID-19 vaccines induces broader neutralizing responses against SARS-CoV-2 variants in comparison with homologous boosters.
Shen X; Hao Y; Wang S; Li D; Ren L; Zhu M; Wang S; Li J; Tang W; Fu Y; Chen R; Liu Y; Shao Y
Vaccine; 2023 Oct; 41(45):6645-6653. PubMed ID: 37770297
[TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia/ZF2001): A randomized, observer-blinded, placebo-controlled trial.
Jin P; Guo X; Chen W; Ma S; Pan H; Dai L; Du P; Wang L; Jin L; Chen Y; Shi F; Liu J; Xu X; Zhang Y; Gao GF; Chen C; Feng J; Li J; Zhu F
PLoS Med; 2022 May; 19(5):e1003953. PubMed ID: 35617368
[TBL] [Abstract][Full Text] [Related]
10. Caveats of chimpanzee ChAdOx1 adenovirus-vectored vaccines to boost anti-SARS-CoV-2 protective immunity in mice.
Cervantes-Torres J; Cabello-Gutiérrez C; Ayón-Núñez DA; Soldevila G; Olguin-Alor R; Diaz G; Acero G; Segura-Velázquez R; Huerta L; Gracia-Mora I; Cobos L; Pérez-Tapia M; Almagro JC; Suárez-Güemes F; Bobes RJ; Fragoso G; Sciutto E; Laclette JP
Appl Microbiol Biotechnol; 2024 Jan; 108(1):179. PubMed ID: 38280035
[TBL] [Abstract][Full Text] [Related]
11. Comparative characterization of antibody responses induced by Ad5-vectored spike proteins of emerging SARS-CoV-2 VOCs.
Wang B; Xu J; Wu S; Zhang Z; Zhao Z; Zhang J; Fu L; Zai X; Wang Y; Zhang G; Chen Z; Chen Y; Sun H; Song X; Zhang J; Zhu L; Hou L; Chen W
Signal Transduct Target Ther; 2022 Jul; 7(1):257. PubMed ID: 35906201
[TBL] [Abstract][Full Text] [Related]
12. A human cell-based SARS-CoV-2 vaccine elicits potent neutralizing antibody responses and protects mice from SARS-CoV-2 challenge.
He X; Ding L; Cao K; Peng H; Gu C; Li Y; Li D; Dong L; Hong X; Wang X; Fu M; Qiu C; Zhu C; Zhang Z; Song S; Wang C; Jiang Z; Xie Y; Qi Z; Zhao C; Zhao P; Zhang X; Xu J
Emerg Microbes Infect; 2021 Dec; 10(1):1555-1573. PubMed ID: 34304724
[TBL] [Abstract][Full Text] [Related]
13. Characterization of immune responses to two and three doses of the adenoviral vectored vaccine ChAdOx1 nCov-19 and the whole virion inactivated vaccine BBV152 in a mix-and-match study in India.
Chaudhary A; Madhavan R; Babji S; Raju R; Syed C; Kumar A; Saravanan P; Sharon Nikitha O; Leander Xavier JV; David Chelladurai JS; Deborah AA; George A; Kang G; Rose W
Vaccine; 2023 Jul; 41(33):4808-4822. PubMed ID: 37357073
[TBL] [Abstract][Full Text] [Related]
14. Prime-boost vaccination of mice and rhesus macaques with two novel adenovirus vectored COVID-19 vaccine candidates.
Luo S; Zhang P; Liu B; Yang C; Liang C; Wang Q; Zhang L; Tang X; Li J; Hou S; Zeng J; Fu Y; Allain JP; Li T; Zhang Y; Li C
Emerg Microbes Infect; 2021 Dec; 10(1):1002-1015. PubMed ID: 33993845
[No Abstract] [Full Text] [Related]
15. Kinetics of vaccine-induced neutralizing antibody titers and estimated protective immunity against wild-type SARS-CoV-2 and the Delta variant: A prospective nationwide cohort study comparing three COVID-19 vaccination protocols in South Korea.
Nham E; Ko JH; Song KH; Choi JY; Kim ES; Kim HJ; Kim B; Lim HY; Kim KC; Jang HC; Lee KH; Song YG; Baek YJ; Ahn JY; Choi JY; Kim YC; Park YS; Choi WS; Bae S; Kim SH; Kang ES; Jeong HW; Kim SW; Kwon KT; Kim SS; Peck KR
Front Immunol; 2022; 13():968105. PubMed ID: 36211416
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and safety of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine: a systematic review.
Lv J; Wu H; Xu J; Liu J
Infect Dis Poverty; 2022 May; 11(1):53. PubMed ID: 35562753
[TBL] [Abstract][Full Text] [Related]
17. Heterologous booster with inhaled adenovirus vector COVID-19 vaccine generated more neutralizing antibodies against different SARS-CoV-2 variants.
Zhong J; Liu S; Cui T; Li J; Zhu F; Zhong N; Huang W; Zhao Z; Wang Z
Emerg Microbes Infect; 2022 Dec; 11(1):2689-2697. PubMed ID: 36197655
[TBL] [Abstract][Full Text] [Related]
18. Heterologous boosting with third dose of coronavirus disease recombinant subunit vaccine increases neutralizing antibodies and T cell immunity against different severe acute respiratory syndrome coronavirus 2 variants.
Wang Z; Zhao Z; Cui T; Huang M; Liu S; Su X; Li G; Song T; Li W; Zhong N; Xu M; Yang X; Huang W
Emerg Microbes Infect; 2022 Dec; 11(1):829-840. PubMed ID: 35230230
[TBL] [Abstract][Full Text] [Related]
19. A modified vaccinia Ankara vaccine expressing spike and nucleocapsid protects rhesus macaques against SARS-CoV-2 Delta infection.
Routhu NK; Gangadhara S; Lai L; Davis-Gardner ME; Floyd K; Shiferaw A; Bartsch YC; Fischinger S; Khoury G; Rahman SA; Stampfer SD; Schäfer A; Jean SM; Wallace C; Stammen RL; Wood J; Joyce C; Nagy T; Parsons MS; Gralinski L; Kozlowski PA; Alter G; Suthar MS; Amara RR
Sci Immunol; 2022 Jun; 7(72):eabo0226. PubMed ID: 35357886
[TBL] [Abstract][Full Text] [Related]
20. Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant.
Zuo F; Abolhassani H; Du L; Piralla A; Bertoglio F; de Campos-Mata L; Wan H; Schubert M; Cassaniti I; Wang Y; Sammartino JC; Sun R; Vlachiotis S; Bergami F; Kumagai-Braesch M; Andréll J; Zhang Z; Xue Y; Wenzel EV; Calzolai L; Varani L; Rezaei N; Chavoshzadeh Z; Baldanti F; Hust M; Hammarström L; Marcotte H; Pan-Hammarström Q
Nat Commun; 2022 May; 13(1):2670. PubMed ID: 35562366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
